Showing 6851-6860 of 7584 results for "".
- Two Galderma Rosacea Therapies Work Well Togetherhttps://practicaldermatology.com/news/two-galderma-rosacea-therapies-work-well-together/2458061/Combined use of Galderma’s SOOLANTRA (ivermectin1% Cream) and Mirvaso (Brimonidine 0.33% Gel) pack a one-two punch against the erythema and inflammatory lesions of rosacea, the MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCe
- Dermira Presents New Data on Late-Stage Programs at European Dermatology Congresshttps://practicaldermatology.com/news/dermira-presents-new-data-on-late-stage-programs-at-european-dermatology-congress/2458066/Dermira, Inc. will present data from its glycopyrronium tosylate (formerly DRM04) and Cimzia (certolizumab pegol) Phase 3 clinical programs in poster sessions at the 26th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Geneva, Switzerland, September 13&
- GBI Research: Global Dermatology Pipeline Will See Shift Toward Increased Use of Biologicshttps://practicaldermatology.com/news/gbi-research-global-dermatology-pipeline-to-see-shift-toward-increased-use-of-biologics/2458071/The global dermatology pipeline, which currently comprises 850 products with a disclosed stage of development, is primarily made up of drugs at an early stage of development, with the late stages of the pipeline dominated by generics and biosimilars, according to GBI Research. The company
- FDA Greenlights Humira Biosim Cyltezo for Multiple Inflammatory Diseaseshttps://practicaldermatology.com/news/fda-greenlights-humira-biosim-cyltezo-for-multiple-inflammatory-diseases/2458073/The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals, Inc.’s Cyltezo™, a biosimilar to Humira®, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including:
- Psoriasis Severity Linked to Increased Risk of Deathhttps://practicaldermatology.com/news/psoriasis-severity-linked-to-increased-risk-of-death/2458074/The more surface area of the body covered by psoriasis, the greater the risk of death, according to a new analysis by researchers at the Perelman School of Medicine at the University of Pennsylvania. In fact, patients with psoriasis on 10 perce
- Bioré Skincare Partners with Girl Uphttps://practicaldermatology.com/news/bior-skincare-partners-with-girl-up/2458081/To celebrate the launch of their new Limited Edition Deep Cleansing Pore Strips, Bioré® Skincare is partnering with Girl Up™, a United Nations Foundation campaign. Girl Up mobilizes girls and women across the globe to raise awareness and funds for United Nations prog
- Survey Highlights Risks of Pubic Hair Groominghttps://practicaldermatology.com/news/survey-highlights-risks-of-pubic-hair-grooming/2458086/More than one-quarter of people who groom their pubic hair sustain grooming-related injuries, according to a new article published by JAMA Dermatology. Of the 7,570 men and women who completed
- Women of Color May Be Disproportionately Exposed to Beauty Product Chemicalshttps://practicaldermatology.com/news/women-of-color-may-be-disproportionately-exposed-to-beauty-product-chemicals/2458087/Women with skin of color have higher levels of beauty-product related chemicals in their bodies compared to white women, according to a commentary published in the American Journal of Obstetrics and Gynecology.<
- Power Couple: Stroll Health Teams Up With First Dermhttps://practicaldermatology.com/news/power-couple-stoll-health-teams-up-with-first-derm/2458085/Stroll Health and First Derm are partnering to make dermatology care more accessible and available at a fair price. Stroll's health care 
- PuraCap Pharmaceuticals Introduces EpiCeram Quad Packhttps://practicaldermatology.com/news/puracap-pharmaceuticals-introduces-epiceram-quad-pack/2458088/PuraCap® Pharmaceutical is introducing the EpiCeram® Controlled Release Skin Barrier Emulsion Quad Pack, which contains four 100-gram airless pumps. EpiCeram® is a US Food and Drug Administration-approved topical prescription e